Annual CFO
-$59.75 M
-$41.65 M-230.11%
December 31, 2024
Summary
- As of March 9, 2025, ARCT annual cash flow from operations is -$59.75 million, with the most recent change of -$41.65 million (-230.11%) on December 31, 2024.
- During the last 3 years, ARCT annual CFO has risen by +$75.30 million (+55.76%).
- ARCT annual CFO is now -286.75% below its all-time high of $31.99 million, reached on December 31, 2022.
Performance
ARCT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$284.00 K
+$23.48 M+98.80%
December 31, 2024
Summary
- As of March 9, 2025, ARCT quarterly cash flow from operations is -$284.00 thousand, with the most recent change of +$23.48 million (+98.80%) on December 31, 2024.
- Over the past year, ARCT quarterly CFO has increased by +$29.86 million (+99.06%).
- ARCT quarterly CFO is now -100.18% below its all-time high of $160.26 million, reached on December 31, 2022.
Performance
ARCT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$59.75 M
+$345.00 K+0.57%
December 31, 2024
Summary
- As of March 9, 2025, ARCT TTM cash flow from operations is -$59.75 million, with the most recent change of +$345.00 thousand (+0.57%) on December 31, 2024.
- Over the past year, ARCT TTM CFO has increased by +$8.99 million (+13.08%).
- ARCT TTM CFO is now -141.84% below its all-time high of $142.79 million, reached on September 30, 2023.
Performance
ARCT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ARCT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -230.1% | +99.1% | +13.1% |
| 3 y3 years | +55.8% | +99.3% | +65.0% |
| 5 y5 years | -827.0% | +99.3% | +65.0% |
ARCT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -286.8% | +55.8% | -100.2% | +99.4% | -141.8% | +65.0% |
| 5 y | 5-year | -286.8% | +55.8% | -100.2% | +99.4% | -141.8% | +65.0% |
| alltime | all time | -286.8% | +55.8% | -100.2% | +99.4% | -141.8% | +65.0% |
Arcturus Therapeutics Holdings Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$59.75 M(+230.1%) | -$284.00 K(-98.8%) | -$59.75 M(-0.6%) |
| Sep 2024 | - | -$23.76 M(-21.2%) | -$60.09 M(-12.6%) |
| Jun 2024 | - | -$30.14 M(+442.4%) | -$68.73 M(-662.7%) |
| Mar 2024 | - | -$5.56 M(+783.5%) | $12.21 M(-167.5%) |
| Dec 2023 | -$18.10 M(-156.6%) | -$629.00 K(-98.1%) | -$18.10 M(-112.7%) |
| Sep 2023 | - | -$32.41 M(-163.8%) | $142.79 M(+7.5%) |
| Jun 2023 | - | $50.81 M(-241.6%) | $132.79 M(+194.0%) |
| Mar 2023 | - | -$35.87 M(-122.4%) | $45.16 M(+41.2%) |
| Dec 2022 | $31.99 M(-123.7%) | $160.26 M(-477.9%) | $31.99 M(-118.7%) |
| Sep 2022 | - | -$42.41 M(+15.2%) | -$170.76 M(+17.8%) |
| Jun 2022 | - | -$36.82 M(-24.9%) | -$145.01 M(+2.7%) |
| Mar 2022 | - | -$49.04 M(+15.4%) | -$141.13 M(+4.5%) |
| Dec 2021 | -$135.04 M(+215.1%) | -$42.50 M(+155.2%) | -$135.04 M(+36.2%) |
| Sep 2021 | - | -$16.65 M(-49.4%) | -$99.18 M(+0.8%) |
| Jun 2021 | - | -$32.94 M(-23.3%) | -$98.40 M(+33.1%) |
| Mar 2021 | - | -$42.95 M(+547.6%) | -$73.95 M(+72.5%) |
| Dec 2020 | -$42.86 M(+565.0%) | -$6.63 M(-58.2%) | -$42.86 M(-2.1%) |
| Sep 2020 | - | -$15.88 M(+86.9%) | -$43.77 M(+42.4%) |
| Jun 2020 | - | -$8.49 M(-28.4%) | -$30.73 M(+138.3%) |
| Mar 2020 | - | -$11.86 M(+57.3%) | -$12.89 M(+100.0%) |
| Dec 2019 | -$6.45 M(-69.0%) | -$7.54 M(+165.8%) | -$6.45 M(+38.0%) |
| Sep 2019 | - | -$2.84 M(-130.4%) | -$4.67 M(-45.9%) |
| Jun 2019 | - | $9.34 M(-272.6%) | -$8.63 M(-66.6%) |
| Mar 2019 | - | -$5.41 M(-6.1%) | -$25.81 M(+24.3%) |
| Dec 2018 | -$20.76 M | -$5.76 M(-15.2%) | -$20.76 M(+107.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$6.79 M(-13.3%) | -$10.00 M(+102.7%) |
| Jun 2018 | - | -$7.84 M(+2072.0%) | -$4.93 M(-219.0%) |
| Mar 2018 | - | -$361.00 K(-107.2%) | $4.14 M(-1000.7%) |
| Dec 2017 | -$460.00 K(-83.9%) | $5.00 M(-389.1%) | -$460.00 K(-106.7%) |
| Sep 2017 | - | -$1.73 M(-240.3%) | $6.90 M(+253.5%) |
| Jun 2017 | - | $1.23 M(-124.8%) | $1.95 M(-157.6%) |
| Mar 2017 | - | -$4.96 M(-140.2%) | -$3.39 M(+18.4%) |
| Dec 2016 | -$2.86 M(-134.5%) | $12.36 M(-285.1%) | -$2.86 M(-141.2%) |
| Sep 2016 | - | -$6.67 M(+62.6%) | $6.94 M(-15.7%) |
| Jun 2016 | - | -$4.11 M(-7.5%) | $8.23 M(-2.5%) |
| Mar 2016 | - | -$4.44 M(-120.0%) | $8.45 M(+1.9%) |
| Dec 2015 | $8.29 M(-129.3%) | $22.16 M(-511.6%) | $8.29 M(-138.4%) |
| Sep 2015 | - | -$5.38 M(+38.3%) | -$21.61 M(-16.0%) |
| Jun 2015 | - | -$3.89 M(-15.3%) | -$25.72 M(-5.8%) |
| Mar 2015 | - | -$4.59 M(-40.6%) | -$27.29 M(-3.6%) |
| Dec 2014 | -$28.33 M(+285.2%) | -$7.74 M(-18.4%) | -$28.33 M(+11.5%) |
| Sep 2014 | - | -$9.49 M(+73.5%) | -$25.41 M(+41.9%) |
| Jun 2014 | - | -$5.47 M(-2.8%) | -$17.91 M(+39.9%) |
| Mar 2014 | - | -$5.63 M(+16.5%) | -$12.80 M(+74.1%) |
| Dec 2013 | -$7.35 M(+364.5%) | -$4.83 M(+142.9%) | -$7.35 M(+191.3%) |
| Sep 2013 | - | -$1.99 M(+460.0%) | -$2.52 M(+370.9%) |
| Jun 2013 | - | -$355.00 K(+96.1%) | -$536.00 K(+196.1%) |
| Mar 2013 | - | -$181.00 K | -$181.00 K |
| Dec 2012 | -$1.58 M(-33.0%) | - | - |
| Dec 2011 | -$2.36 M | - | - |
FAQ
- What is Arcturus Therapeutics Holdings annual cash flow from operations?
- What is the all time high annual CFO for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings annual CFO year-on-year change?
- What is Arcturus Therapeutics Holdings quarterly cash flow from operations?
- What is the all time high quarterly CFO for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings quarterly CFO year-on-year change?
- What is Arcturus Therapeutics Holdings TTM cash flow from operations?
- What is the all time high TTM CFO for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings TTM CFO year-on-year change?
What is Arcturus Therapeutics Holdings annual cash flow from operations?
The current annual CFO of ARCT is -$59.75 M
What is the all time high annual CFO for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high annual cash flow from operations is $31.99 M
What is Arcturus Therapeutics Holdings annual CFO year-on-year change?
Over the past year, ARCT annual cash flow from operations has changed by -$41.65 M (-230.11%)
What is Arcturus Therapeutics Holdings quarterly cash flow from operations?
The current quarterly CFO of ARCT is -$284.00 K
What is the all time high quarterly CFO for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high quarterly cash flow from operations is $160.26 M
What is Arcturus Therapeutics Holdings quarterly CFO year-on-year change?
Over the past year, ARCT quarterly cash flow from operations has changed by +$29.86 M (+99.06%)
What is Arcturus Therapeutics Holdings TTM cash flow from operations?
The current TTM CFO of ARCT is -$59.75 M
What is the all time high TTM CFO for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high TTM cash flow from operations is $142.79 M
What is Arcturus Therapeutics Holdings TTM CFO year-on-year change?
Over the past year, ARCT TTM cash flow from operations has changed by +$8.99 M (+13.08%)